HAVE MERCY ON WOCKHARDT SCRIP

After hitting a lifetime high of Rs 2168 in May 2013, the Wockhardt scrip has been hammered out of shape. It hit a low of Rs 340 three weeks ago and now hovers between Rs 449 and Rs 470. Huge volumes are noticed daily in both exchanges but the big-giveaway of manipulation is delivery of 11 per cent on most days.

The stacks are against the trader. 74 per cent Equity with Promoters and 15 per cent with FII/MF/DIIs means there is little chance of a fund exiting without hitting a lower circuit or a large buyer coming and hitting an upper circuit. Which such lopsided shareholding it might be better to put the scrip into the T group and stop the 5 lower circuit and 3 upper circuit type of moves.

The Q1 results inspite of known problems-the USFDA and UKMHRA import alerts for the Waluj facility, the DCGI banning sale of Spasmoproxyvon in the country and now chikalthana facility too under USFDA observations, the numbers were bad.

Q1 consolidated sales were up 1 per cent, and EBIT and PAT declined by 13 and 14 per cent respectively in the 3 months to June 2013. The overall operations too have turned out to be bad.

Wockhardt’s International Business contributed 82% of the Total Revenues during the quarter.

Wockhardt’s US business recorded a growth of 11% in Q1FY14 and contributed 53% of the Global Revenues for Wockhardt

The UK business recorded a growth of 1% in Q1FY14. The Irish market recorded a decline of 31% in Q1FY14.

The India business grew by 3% and the Emerging Markets business declined by 28% in Q1FY14.